HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells

Journal of Biomolecular Structure and Dynamics

Volumn 33, Issue 6, 2015, Pages 1185-1197

  Ganai, Shabir Ahmad ^a   Malli Kalladi, Shashwath ^a   Mahadevan, Vijayalakshmi ^a  

^a SASTRA UNIVERSITY   (India)

Author keywords

developmental kinases; histone deacetylase inhibitor; human embryonic kidney cells; immunofluorescence; molecular mechanics generalised born surface area; valproic acid

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LIGAND; PROTEIN BINDING; PROTEIN KINASE C BETA; VALPROIC ACID;

CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; HEK293 CELL LINE; HUMAN; METABOLISM; METHYLATION;

CATALYTIC DOMAIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; LIGANDS; METHYLATION; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN KINASE C BETA; VALPROIC ACID;

EID: 84939891117     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2014.938247     Document Type: Article

References (73)

1. Bachmann, I. M., Halvorsen, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A.,., Akslen, L. A. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology, 24, 268-273.
2. Bartova, E., Pachernik, J., Harnicarova, A., Kovarik, A., Kovarikova, M., Hofmanova, J.,., Kozubek, S. (2005). Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases. Journal of Cell Science, 118, 5035-5046.
3. Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J.,., Lander, E. S. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 125, 315-326.
4. Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I.,., Jaenisch, R. (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature, 441, 349-353.
5. Brilli, L. L., Swanhart, L. M., Caestecker, M. P., Hukriede, N. A. (2013). HDAC inhibitors in kidney development and disease. Pediatric Nephrology, 28, 1909-1921.
6. Buch, I., Fishelovitch, D., London, N., Raveh, B., Wolfson, H. J., Nussinov, R. (2010). Allosteric regulation of glycogen synthase kinase 3beta: A theoretical study. Biochemistry, 49, 10890-10901.
7. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P.,., Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039-1043.
8. Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., Ingber, D. E. (1997). Geometric control of cell life and death. Science, 276, 1425-1428.
9. Christensen, J., Agger, K., Cloos, P. A., Pasini, D., Rose, S., Sennels, L.,., Helin, K. (2007). RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell, 128, 1063-1076.
10. Collett, K., Eide, G. E., Arnes, J., Stefansson, I. M., Eide, J., Braaten, A.,., Akslen, L. A. (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research, 12, 1168-1174.
11. Consalvi, S., Saccone, V., Giordani, L., Minetti, G., Mozzetta, C., Puri, P. L. (2011). Histone deacetylase inhibitors in the treatment of muscular dystrophies: Epigenetic drugs for genetic diseases. Molecular Medicine, 17, 457-465.
12. Cunliffe, V. T. (2008). Eloquent silence: Developmental functions of class I histone deacetylases. Current Opinion in Genetics & Development, 18, 404-410.
13. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochemical Journal, 370, 737-749.
14. Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358, 1148-1159.
15. Ezhkova, E., Lien, W. H., Stokes, N., Pasolli, H. A., Silva, J. M., Fuchs, E. (2011). EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes & Development, 25, 485-498.
16. Fischle, W., Wang, Y., Jacobs, S. A., Kim, Y., Allis, C. D., Khorasanizadeh, S. (2003). Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes and Development, 17, 1870-1881.
17. Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A.,., Bhalla, K. N. (2009). Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 114, 2733-2743.
18. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A.,., Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49, 6177-6196.
19. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S.,., Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The Embo Journal, 20, 6969-6978.
20. Grodsky, N., Li, Y., Bouzida, D., Love, R., Jensen, J., Nodes, B.,., Grant, S. (2006). Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry, 45, 13970-13981.
21. Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. Nature, 389, 349-352.
22. Hertzog, R. G., Hertzog, D. I., Patrinichi, B. (2009). Cytochemical study regarding the effect of trichostatin A on cell cultures. Therapeutics, Pharmacology and Clinical Toxicology, XIII. 154-160.
23. Holler, C., Pinõn, J. D., Denk, U., Heyder, C., Hofbauer, S., Greil, R., Egle, A. (2009). PKCβ is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: Validation of PKCβ as a therapeutic target in chronic lymphocytic leukemia. Blood, 113, 2791-2794.
24. Hu, E., Dul, E., Sung, C. M., Chen, Z., Kirkpatrick, R., Zhang, G. F.,., Jaye, M. (2003). Identification of novel isoform-selective inhibitors within class I histone deacetylases. Journal of Pharmacology and Experimental Therapeutics, 307, 720-728.
25. Huang, P. H., Chen, C. H., Chou, C. C., Sargeant, A. M., Kulp, S. K., Teng, C. M.,., Chen, C. S. (2011). Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Molecular Pharmacology, 79, 197-206.
26. Hur, E. M., Zhou, F. Q. (2010). GSK3 signalling in neural development. Nature Reviews Neuroscience, 11, 539-551.
27. Johannessen, C. U., Johannessen, S. I. (2003). Valproate: Past, present, and future. CNS Drug Reviews, 9, 199-216.
28. Karagiannis, T. C., El-Osta, A. (2006). Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics, 1, 121-126.
29. Kim, H. J., Bae, S. C. (2011). Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research, 3, 166-179.
30. Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A.,., Chinnaiyan, A. M. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 11606-11611.
31. Kuo, M. H., Allis, C. D. (1998). Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays, 20, 615-626.
32. Le Beyec, J., Xu, R., Lee, S. Y., Nelson, C. M., Rizki, A., Alcaraz, J., Bissell, M. J. (2007). Cell shape regulates global histone acetylation in human mammary epithelial cells. Experimental Cell Research, 313, 3066-3075.
33. Lee, M. G., Wynder, C., Bochar, D. A., Hakimi, M. A., Cooch, N., Shiekhattar, R. (2006). Functional interplay between histone demethylase and deacetylase enzymes. Molecular and Cellular Biology, 26, 6395-6402.
34. Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M.,., Young, R. A. (2006). Control of developmental regulators by Polycomb in human embryonic stem cells. Cell, 125, 301-313.
35. Legube, G., Trouche, D. (2003). Regulating histone acetyltransferases and deacetylases. EMBO Reports, 4, 944-947.
36. Lig Prep. 2012. Schrodinger (Version 2.5). New York, NY: LLC.
37. Liu, S., Cheng, H., Kwan, W., Lubieniecka, J. M., Nielsen, T. O. (2008). Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Molecular Cancer Therapeutics, 7, 1751-1761.
38. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., Richmond, T. J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 389, 251-260.
39. Luo, J. (2012). The role of GSK3beta in the development of the central nervous system. Frontiers in Biology, 7, 212-220.
40. Lyne, P. D., Lamb, M. L., Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49, 4805-4808.
41. Mannironi, C., Proietto, M., Bufalieri, F., Cundari, E., Alagia, A., Danovska, S.,., Negri, R. (2014). An high-throughput in vivo screening system to select H3K4-specific histone demethylase inhibitors. PLoS One, 9, e86002.
42. Marchion, D. C., Bicaku, E., Daud, A. I., Sullivan, D. M., Munster, P. N. (2005). Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Research, 65, 3815-3822.
43. Margueron, R., Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. Nature, 469, 343-349.
44. Marinova, Z., Leng, Y., Leeds, P., Chuang, D. M. (2011). Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. Neuropharmacology, 60, 1109-1115.
45. Martín-Sánchez, E., Sánchez-Beato, M., Rodríguez, M. E., Sánchez-Espiridión, B., Gómez-Abad, C., Bischoff, J. R.,., Garciá, J. F. (2011). HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. British Journal of Haematology, 152, 352-356.
46. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S.,., Creasy, C. L. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 492, 108-112.
47. Milutinovic, S., DAlessio, A. C., Detich, N., Szyf, M. (2007). Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis, 28, 560-571.
48. Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L.,., Meyn, R. E. (2005). Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clinical Cancer Research, 11, 4912-4922.
49. Nightingale, K. P., Gendreizig, S., White, D. A., Bradbury, C., Hollfelder, F., Turner, B. M. (2007). Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. Journal of Biological Chemistry, 282, 4408-4416.
50. Nowak, S. J., Corces, V. G. (2004). Phosphorylation of histone H3: A balancing act between chromosome condensation and transcriptional activation. Trends in Genetics, 20, 214-220.
51. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., Klein, P. S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry, 276, 36734-36741.
52. Raman, J. D., Mongan, N. P., Tickoo, S. K., Boorjian, S. A., Scherr, D. S., Gudas, L. J. (2005). Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clinical Cancer Research, 11, 8570-8576.
53. Ringrose, L., Paro, R. (2004). Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annual Review of Genetics, 38, 413-443.
54. Saha, A., Wittmeyer, J., Cairns, B. R. (2006). Chromatin remodelling: The industrial revolution of DNA around histones. Nature Reviews Molecular Cell Biology, 7, 437-447.
55. Salam, N. K., Nuti, R., Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49, 2356-2368
56. Sayegh, J., Cao, J., Zou, M. R., Morales, A., Blair, L. P., Norcia, M.,., Yan, Q. (2013). Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. Journal of Biological Chemistry, 288, 9408-9417.
57. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., Cavalli, G. (2007). Genome regulation by polycomb and trithorax proteins. Cell, 128, 735-745.
58. Spina, E., Perugi, G. (2004). Antiepileptic drugs: Indications other than epilepsy. Epileptic Disorders, 6, 57-75.
59. Spittaels, K., Van den Haute, C., Van Dorpe, J., Terwel, D., Vandezande, K., Lasrado, R.,., Van Leuven, F. (2002). Neonatal neuronal overexpression of glycogen synthase kinase-3β reduces brain size in transgenic mice. Neuroscience, 113, 797-808.
60. Sproul, D., Gilbert, N., Bickmore, W. A. (2005). The role of chromatin structure in regulating the expression of clustered genes. Nature Reviews Genetics, 6, 775-781.
61. Strahl, B. D., Allis, C. D. (2000). The language of covalent histone modifications. Nature, 403, 41-45.
62. Van Damme, M., Crompot, E., Meuleman, N., Mineur, P., Bron, D., Lagneaux, L., Stamatopoulos, B. (2012). HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics, 7, 1403-1412.
63. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G.,., Chinnaiyan, A. M. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
64. Vergani, L., Grattarola, M., Nicolini, C. (2004). Modifications of chromatin structure and gene expression following induced alterations of cellular shape. The International Journal of Biochemistry & Cell Biology, 36, 1447-1461.
65. Ververis, K., Hiong, A., Karagiannis, T. C., Licciardi, P. V. (2013). Histone deacetylase inhibitors (HDACIs): Multitargeted anticancer agents. Biologics, 7, 47-60.
66. Wang, G. G., Song, J., Wang, Z., Dormann, H. L., Casadio, F., Li, H.,., Allis, C. D. (2009). Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature, 459, 847-851.
67. Way, K. J., Katai, N., King, G. L. (2001). Protein kinase C and the development of diabetic vascular complications. Diabetic Medicine, 18, 945-959.
68. Weake, V. M., Workman, J. L. (2008). Histone ubiquitination: Triggering gene activity. Molecular Cell, 29, 653-663.
69. Wu, C. (1997). Chromatin remodeling and the control of gene expression. Journal of Biological Chemistry, 272, 28171-28174.
70. Yang, X. J., Seto, E. (2007). HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 26, 5310-5318.
71. Yildirim, E., Zhang, Z., Uz, T., Chen, C. Q., Manev, R., Manev, H. (2003). Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neuroscience Letters, 345, 141-143.
72. Zhang, K., Siino, J. S., Jones, P. R., Yau, P. M., Bradbury, E. M. (2004). A mass spectrometric "Western blot" to evaluate the correlations between histone methylation and histone acetylation. Proteomics, 4, 3765-3775.
73. Zhao, Y., Xing, B., Dang, Y. H., Qu, C. L., Zhu, F., Yan, C. X. (2013). Microinjection of valproic acid into the ventrolateral orbital cortex enhances stress-related memory formation. PLoS One, 8, e52698.